Urine pp 189-194 | Cite as

Serial Changes of Urinary Proteome in Animal Models of Renal Diseases

  • Mindi Zhao
  • Yuan Yuan


Urine is directly connected to the urinary system; as a result, urine proteome was usually used for renal diseases. As urine accumulates all types of changes, identifying the precise cause of changes in the urine proteome is challenging and crucial in biomarker discovery. To reduce the confounding factors to minimal, some studies used animal model resembling human diseases. This chapter highlights the importance of animal models and introduces two strategic researches which focused on serial changes of urine proteome in animal model of focal segmental glomerulosclerosis and tubular injury. In these studies, urine samples were collected at different stages of animal models, and urinary proteins were profiled by LC-MS/MS. For the focal segmental glomerulosclerosis model, 25 urinary proteins changed in the whole process. For the unilateral ureteral obstruction model, 7 and 19 significantly changed in the 1- and 3-week groups, respectively. We think these stage-dependent dynamic changes of urine proteome in animal models will help to support the role of urine as key source in biomarker discovery especially in kidney diseases and help to identify corresponding biomarkers for clinical validation.


Urinary proteome Renal diseases Animal models 



A part of this chapter is reused with permission from our previous published book chapter, Zhao M. (2015) Human Urine Proteome: A Powerful Source for Clinical Research. In: Gao Y. (eds) Urine Proteomics in Kidney Disease Biomarker Discovery. Advances in Experimental Medicine and Biology, vol 845. Springer, Dordrecht, and our previous published paper, Yuan, Yuan Y…Gao Y. “Urinary candidate biomarker discovery in a rat unilateral ureteral obstruction model,” Scientific Reports, 2015.


  1. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 2006;7:R80.CrossRefGoogle Scholar
  2. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009;75:1145–52.CrossRefGoogle Scholar
  3. Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, et al. Urine in clinical proteomics. Mol Cell proteomics. 2008;7:1850–62.CrossRefGoogle Scholar
  4. Grande MT, Lopez-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol. 2009;5:319–28.CrossRefGoogle Scholar
  5. Haynes PA, Yates JR 3rd. Proteome profiling-pitfalls and progress. Yeast. 2000;17:81–7.CrossRefGoogle Scholar
  6. Jia L, Zhang L, Shao C, Song E, et al. An attempt to understand kidney’s protein handling function by comparing plasma and urine proteomes. PLoS One. 2009;4:e5146.CrossRefGoogle Scholar
  7. Jia L, Li X, Shao C, Wei L, et al. Using an isolated rat kidney model to identify kidney origin proteins in urine. PLoS One. 2013;8:e66911.CrossRefGoogle Scholar
  8. Kandasamy N, Ashokkumar N. Protective effect of bioflavonoid myricetin enhances carbohydrate metabolic enzymes and insulin signaling molecules in streptozotocin-cadmium induced diabetic nephrotoxic rats. Toxicol Appl Pharmacol. 2014;279:173–85.CrossRefGoogle Scholar
  9. Kitiyakara C, Kopp JB, Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23:172–82.CrossRefGoogle Scholar
  10. Klein J, Schanstra JP. Implementation of proteomics biomarkers in nephrology: from animal models to human application? Proteomics Clin Appl. 2018:e1800089.Google Scholar
  11. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int. 1998;54:687–97.CrossRefGoogle Scholar
  12. Li QR, Fan KX, Li RX, Dai J, et al. A comprehensive and non-prefractionation on the protein level approach for the human urinary proteome: touching phosphorylation in urine. Rapid Commun Mass Spectrom. 2010;24:823–32.CrossRefGoogle Scholar
  13. Marimuthu A, O’Meally RN, Chaerkady R, Subbannayya Y, et al. A comprehensive map of the human urinary proteome. J Proteome Res. 2011;10:2734–43.CrossRefGoogle Scholar
  14. Minarowska A, Minarowski L, Karwowska A, Sands D, Dabrowska E. The activity of cathepsin D in saliva of cystic fibrosis patients. Folia Histochem Cytobiol. 2007;45:165–8.PubMedGoogle Scholar
  15. Moles A, Tarrats N, Fernandez-Checa JC, Mari M. Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology. 2009;49:1297–307.CrossRefGoogle Scholar
  16. Ngai HH, Sit WH, Jiang PP, Xu RJ, et al. Serial changes in urinary proteome profile of membranous nephropathy: implications for pathophysiology and biomarker discovery. J Proteome Res. 2006;5:3038–47.CrossRefGoogle Scholar
  17. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, Durvasula RV, et al. Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol. 2009;296:F213–29.CrossRefGoogle Scholar
  18. Rampanelli E, Rouschop KM, Claessen N, Teske GJ, et al. Opposite role of CD44-standard and CD44-variant-3 in tubular injury and development of renal fibrosis during chronic obstructive nephropathy. Kidney Int. 2014;86:558–69.CrossRefGoogle Scholar
  19. Saha S, Harrison SH, Shen C, Tang H, et al. HIP2: an online database of human plasma proteins from healthy individuals. BMC Med Genet. 2008;1:12.Google Scholar
  20. Schaffer P, Molnar L, Lukasz P, Mattyus I, et al. Urinary enzyme excretion in childhood uropathy. Orv Hetil. 2002;143:2135–9.PubMedGoogle Scholar
  21. Shao C, Li M, Li X, Wei L, et al. A tool for biomarker discovery in the urinary proteome: a manually curated human and animal urine protein biomarker database. Mol Cell Proteomics. 2011;10:M111.010975.CrossRefGoogle Scholar
  22. Sharma V, Tikoo K. Stage-specific quantitative changes in renal and urinary proteome during the progression and development of streptozotocin-induced diabetic nephropathy in rats. Mol Cell Biochem. 2014;388:95–111.CrossRefGoogle Scholar
  23. Silverstein DM, Travis BR, Thornhill BA, Schurr JS, et al. Altered expression of immune modulator and structural genes in neonatal unilateral ureteral obstruction. Kidney Int. 2003;64:25–35.CrossRefGoogle Scholar
  24. Tampe B, Zeisberg M. Contribution of genetics and epigenetics to progression of kidney fibrosis. Nephrol Dial Transplant. 2014;29(Suppl 4):iv72–9.CrossRefGoogle Scholar
  25. Thomas DB. Focal segmental glomerulosclerosis: a morphologic diagnosis in evolution. Arch Pathol Lab Med. 2009;133:217–23.PubMedGoogle Scholar
  26. Wang Y, Chen Y, Zhang Y, Wu S, et al. Differential ConA-enriched urinary proteome in rat experimental glomerular diseases. Biochem Biophys Res Commun. 2008;371:385–90.CrossRefGoogle Scholar
  27. Yuan Y, Zhang F, Wu J, Shao C, Gao Y. Urinary candidate biomarker discovery in a rat unilateral ureteral obstruction model. Sci Rep. 2015;5:9314.CrossRefGoogle Scholar
  28. Zhao M, Li M, Li X, Shao C, et al. Dynamic changes of urinary proteins in a focal segmental glomerulosclerosis rat model. Proteome Sci. 2014;12:42.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Mindi Zhao
    • 1
  • Yuan Yuan
    • 2
  1. 1.Department of Laboratory Medicine, Beijing HospitalNational Center of GerontologyBeijingChina
  2. 2.Department of Pathology, Beijing Tiantan HospitalCapital Medical UniversityBeijingChina

Personalised recommendations